Carboplatin (Paraplatin)

General information

Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.

Route: IV
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp,Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.

Dosing information

• Carboplatin AUC calculator

Calvert formula

• Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748-56. link to original article contains verified formula PubMed

Diseases for which it is established (work in progress)

• Malignant pleural mesothelioma
• Non-small cell lung cancer
  • Non-small cell lung cancer, nonsquamous
  • Non-small cell lung cancer, squamous
• Ovarian cancer

Diseases for which it is used

• Adult T-cell leukemia-lymphoma
• Anal cancer
• Anaplastic glioma
• Breast cancer
• Cervical cancer
• Diffuse large B-cell lymphoma
• Endometrial cancer
• Esophageal cancer
• Ewing sarcoma
• Extranodal NK- and T-cell lymphoma, nasal type
• Gastric cancer
• Glioblastoma
• Head and neck cancer
• Classical Hodgkin lymphoma
• Low-grade glioma
  • Low-grade glioma, pediatric
• Mantle cell lymphoma
• Medulloblastoma
• Melanoma
• Nasopharyngeal carcinoma
• Neuroblastoma
• Osteosarcoma
• Prostate cancer
• Small cell lung cancer
• Testicular cancer
• Thymoma
• Unknown primary
• Urothelial carcinoma
  • Bladder cancer
  • Upper tract urothelial carcinoma

Diseases for which it was used

• Pancreatic cancer

Patient drug information

• Carboplatin (Paraplatin) package insert
• Carboplatin (Paraplatin) patient drug information (Chemocare)
• Carboplatin (Paraplatin) patient drug information (UpToDate)

History of changes in FDA indication

• 1989-03-03: Initial approval as palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have previously been treated with cisplatin. (Based on SWOG 8412 and Swenerton et al. 1992)

History of changes in EMA indication

• 1986-01-23: EURD

History of changes in PMDA indication

• 2011-11-25: New additional indication and new dosages for the treatment of breast cancer.

Also known as

• Code name: JM-8
• Brand names:

Synonyms
Biocarb	Biocarbo	Bioplatinex	Biovinate	Blastocarb	Bonaplatin	Boplatex	Carbo
Carbokem	Carbomedac	Carbomerck	Carboplat	Carboplatine	Carboplatino	Carboplatinum	Carbosin
Carbotanil	Carbotec	Carbotinol	Careptin	Carplan	Carplanil	Carpsol	Crobextin
Cycloplatin	Cycloplatinum	Emorzim	Erbakar	Ercar	Fauldcarbo	Ifacap	Kemocarb
Megaplatin	Nealorin	Neocarb	Neocarbo	Oncocarb	Paraplatin	Paraplatine	Pharmaplatin
Platamine CS	Platinwas	Ribocarbo	Tecnocarb	Vancel	CBDCA